Compare NNOX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNOX | SERA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 75.2M |
| IPO Year | 2019 | 2021 |
| Metric | NNOX | SERA |
|---|---|---|
| Price | $0.79 | $2.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 27.4K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $147.55 | $554.81 |
| Revenue Next Year | $81.13 | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.73 | $1.56 |
| 52 Week High | $4.71 | $3.95 |
| Indicator | NNOX | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 31.79 | 55.96 |
| Support Level | $0.73 | $1.79 |
| Resistance Level | $1.16 | $2.21 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 2.85 | 76.33 |
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.